JOURNAL OF PHARMACEUTICAL SCIENCES

metrics 2024

Fostering collaboration for groundbreaking pharmaceutical discoveries.

Introduction

The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

Metrics 2024

SCIMAGO Journal Rank0.70
Journal Impact Factor3.70
Journal Impact Factor (5 years)3.50
H-Index206
Journal IF Without Self3.70
Eigen Factor0.01
Normal Eigen Factor2.01
Influence0.60
Immediacy Index1.40
Cited Half Life11.60
Citing Half Life8.60
JCI0.87
Total Documents8674
WOS Total Citations26522
SCIMAGO Total Citations84336
SCIMAGO SELF Citations8400
Scopus Journal Rank0.70
Cites / Document (2 Years)3.66
Cites / Document (3 Years)3.73
Cites / Document (4 Years)3.73

Metrics History

Rank 2024

Scopus

Pharmaceutical Science in Pharmacology, Toxicology and Pharmaceutics
Rank #36/183
Percentile 80.33
Quartile Q1

IF (Web Of Science)

CHEMISTRY, MEDICINAL
Rank 29/72
Percentile 60.40
Quartile Q2
CHEMISTRY, MULTIDISCIPLINARY
Rank 84/230
Percentile 63.70
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 90/354
Percentile 74.70
Quartile Q2

JCI (Web Of Science)

CHEMISTRY, MEDICINAL
Rank 28/72
Percentile 61.11
Quartile Q2
CHEMISTRY, MULTIDISCIPLINARY
Rank 69/231
Percentile 70.13
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 109/354
Percentile 69.21
Quartile Q2

Quartile History

Similar Journals

Istanbul Journal of Pharmacy

Discovering innovations in pharmaceutical sciences.
Publisher: ISTANBUL UNIV, FAC PHARMACYISSN: Frequency: 3 issues/year

Istanbul Journal of Pharmacy, published by Istanbul University, Faculty of Pharmacy, is a pivotal platform dedicated to the advancement of pharmaceutical sciences and technology. This journal serves as a vital resource for researchers, professionals, and students alike, seeking to disseminate cutting-edge research, reviews, and innovative methodologies within the pharmaceutical discipline. With a commitment to open access, the journal aims to foster a collaborative environment that promotes information sharing and scholarly discourse. The Istanbul Journal of Pharmacy invites submissions that delve into diverse topics ranging from drug formulation to pharmacokinetics, ensuring that readers are equipped with the latest insights and discoveries in the field. This journal is positioned to enhance scientific communication within the pharmaceutical community and support the continuous evolution of pharmacy practice and education globally.

MOLECULAR PHARMACEUTICS

Fostering Collaboration in Pharmaceutical Science Research
Publisher: AMER CHEMICAL SOCISSN: 1543-8384Frequency: 6 issues/year

MOLECULAR PHARMACEUTICS, published by the American Chemical Society, stands as a pivotal journal within the fields of Drug Discovery, Molecular Medicine, and Pharmaceutical Science, as evidenced by its impressive rankings in various categories, including Q1 in Drug Discovery and Pharmaceutical Science. With an ISSN of 1543-8384 and an E-ISSN of 1543-8392, this journal has been at the forefront of research since its inception in 2004 and continues to foster innovation and collaboration among researchers, professionals, and students well into 2024. The journal is noted for its significant impact, having achieved a Scopus ranking of #31 in Pharmaceutical Science and #36 in Drug Discovery, placing it in the top percentiles of the respective fields. While it currently does not offer Open Access, MOLECULAR PHARMACEUTICS remains an essential resource for advancing the understanding of molecular mechanisms in drug development and therapeutic strategies, ensuring that cutting-edge findings reach a wide audience and contribute to the progression of pharmaceutical sciences.

INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES

Exploring novel methodologies in drug development.
Publisher: INDIAN PHARMACEUTICAL ASSOCISSN: 0250-474XFrequency: 6 issues/year

Indian Journal of Pharmaceutical Sciences, with ISSN 0250-474X and E-ISSN 1998-3743, is a notable publication in the field of Pharmaceutical Sciences, published by the esteemed Indian Pharmaceutical Association. Established in 1978, this journal has been pivotal in disseminating innovative research findings and advancements in pharmaceutical sciences for over four decades. Though no longer covered in Scopus post-2022, its contributions through published works remain relevant to the academic community, ranking in the bottom half of the Scopus percentile for the pharmaceutical category. The journal offers a valuable platform for researchers, professionals, and students to share knowledge and foster collaboration, with a focus on novel methodologies, pharmacological studies, and toxicology. While the journal is not Open Access, it provides essential insights into the evolving landscape of pharmaceutical sciences, making it a key resource for anyone involved in this dynamic field.

International Journal of Pharmaceutical Investigation

Elevating Standards in Pharmaceutical Scholarship
Publisher: INPHARM ASSOC, PHCOG NETISSN: 2230-973XFrequency: 4 issues/year

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

Journal of Reports in Pharmaceutical Sciences

Connecting Scholars and Practitioners in Drug Development.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Innovative Insights for Enhanced Drug Formulation and Safety.
Publisher: TAYLOR & FRANCIS LTDISSN: 1083-7450Frequency: 6 issues/year

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

ACTA PHARMACEUTICA

Elevating discussions in medicine and pharmaceutical sciences.
Publisher: SCIENDOISSN: 1330-0075Frequency: 4 issues/year

ACTA PHARMACEUTICA is a distinguished open-access journal published by SCIENDO, dedicated to advancing knowledge in the fields of medicine and pharmaceutical sciences. Established in 1992, the journal has made significant contributions to the scholarly community, providing a platform for innovative research and discussion. With a strong presence in both Q2 and Q3 quartiles across various categories including Pharmaceutical Science and Pharmacology, ACTA PHARMACEUTICA ranks favorably, positioning its contributions in the upper tiers of the field. The journal's commitment to open access since 2007 ensures that both practitioners and scholars have immediate access to cutting-edge developments, thereby fostering collaboration and knowledge sharing. With its scope spanning a broad spectrum of pharmaceutical and biomedical research, ACTA PHARMACEUTICA is an essential resource for researchers, professionals, and students keen to stay abreast of the latest advancements and trends in these vital areas of study.

International Journal of Pharmaceutics-X

Catalyzing collaboration in cutting-edge pharmaceutical research.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.

DARU-Journal of Pharmaceutical Sciences

Bridging research and practice in pharmaceutical sciences.
Publisher: SPRINGER INT PUBL AGISSN: Frequency: 2 issues/year

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Acta Pharmaceutica Sinica B

Publishing Tomorrow's Pharmaceutical Breakthroughs Today
Publisher: INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCESISSN: 2211-3835Frequency: 6 issues/year

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.